Mesoblast (MEOBF) Cash & Equivalents (2017 - 2025)

Mesoblast (MEOBF) has disclosed Cash & Equivalents for 9 consecutive years, with $161.6 million as the latest value for Q2 2025.

  • Quarterly Cash & Equivalents rose 156.59% to $161.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $161.6 million through Jun 2025, up 156.59% year-over-year, with the annual reading at $161.6 million for FY2025, 156.59% up from the prior year.
  • Cash & Equivalents hit $161.6 million in Q2 2025 for Mesoblast, up from $63.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $161.6 million in Q2 2025 to a low of $60.4 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $98.6 million across 5 years, with a median of $71.3 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 55.84% in 2022 and later surged 156.59% in 2025.
  • Year by year, Cash & Equivalents stood at $136.9 million in 2021, then crashed by 55.84% to $60.4 million in 2022, then grew by 17.98% to $71.3 million in 2023, then dropped by 11.72% to $63.0 million in 2024, then soared by 156.59% to $161.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for MEOBF at $161.6 million in Q2 2025, $63.0 million in Q2 2024, and $71.3 million in Q2 2023.